BioCardia Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2010
Net Income	-10.34	-11.57	-11.91	-12.62	-15	-14.71	Upgrade
Depreciation & Amortization	0.42	0.41	0.38	0.64	0.07	0.55	Upgrade
Share-Based Compensation	0.96	1.03	1.18	1.66	2.95	2.72	Upgrade
Other Operating Activities	0.02	0.16	-0.21	-0.04	-0.37	1.99	Upgrade
Operating Cash Flow	-8.94	-9.97	-10.56	-10.37	-12.36	-9.45	Upgrade
Capital Expenditures	-0	-0.01	-0.07	-0.12	-0.03	-0.15	Upgrade
Investing Cash Flow	-0	-0.01	-0.07	-0.12	-0.03	-0.15	Upgrade
Share Issuance / Repurchase	5.04	3.73	5.12	1.95	27.87	9.19	Upgrade
Debt Issued / Paid	0	0	0	0	0.51	0.63	Upgrade
Other Financing Activities	-	-	-	-	-0.16	-	Upgrade
Financing Cash Flow	5.04	3.73	5.12	1.95	28.21	9.82	Upgrade
Net Cash Flow	-3.91	-6.26	-5.51	-8.54	15.82	0.23	Upgrade
Free Cash Flow	-8.95	-9.99	-10.63	-10.48	-12.39	-9.59	Upgrade
Free Cash Flow Margin	-1911.54%	-2093.50%	-786.32%	-1032.71%	-8544.14%	-1350.85%	Upgrade
Free Cash Flow Per Share	-5.34	-7.07	-9.00	-9.29	-18.37	-25.49	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).